Mixtures of endocrine-disrupting contaminants induce adverse developmental effects in preweaning rats

Marta Axelstad, Sofie Christiansen, Julie Boberg, Martin Scholze, Pernille Rosenskjold Jacobsen, Louise Krag Isling, Andreas Kortenkamp and Ulla Hass

Division of Toxicology and Risk Assessment, National Food Institute, Technical University of Denmark, Mørkhøj Bygade 19, DK-2860 Søborg, Denmark and Institute for the Environment, Brunel University, Kingston Lane, Uxbridge, Middlesex UB8 3PH, UK

Correspondence should be addressed to M Axelstad; Email: maap@food.dtu.dk

Abstract

Reproductive toxicity was investigated in rats after developmental exposure to a mixture of 13 endocrine-disrupting contaminants, including pesticides, plastic and cosmetic ingredients, and paracetamol. The mixture was composed on the basis of information about high-end human exposures, and the dose levels reflecting 100, 200, and 450 times this exposure were tested. The compounds were also grouped according to their estrogenicity or anti-androgenicity, and their joint effects were tested at two different doses, with each group reflecting 200 or 450 times human exposure. In addition, a single paracetamol dose was tested (350 mg/kg per day). All exposures and a vehicle were administered by oral gavage to time-mated Wistar dams rats throughout gestation and lactation, and their offspring were assessed for reproductive effects at birth and in prepuberty. The mixture doses, which included the anti-androgenic compounds, affected the male offspring by causing decreased anogenital distance, increased nipple retention (NR), and reduced ventral prostate weights, at both medium and high doses. In addition, the weights of the levator ani/bulbocavernous muscle (LABC) were decreased at the high dose of anti-androgen mixture. No effects were seen after exposure to the estrogenic chemicals alone, whereas males exposed solely to paracetamol showed decreased LABC weights and increased NR. Thus adverse reproductive effects were observed at mixtures reflecting 200 times high-end human exposure, which is relatively close to the safety margin covered by the regulatory uncertainty factor of 100. This suggests that highly exposed human population groups may not be sufficiently protected against mixtures of endocrine-disrupting chemicals.

Reproduction (2014) 147 489–501

Introduction

There is good evidence from animal studies that developmental exposure to environmental agents with endocrine-disrupting properties can cause adverse reproductive effects, including decreased anogenital distance (AGD), increased nipple retention (NR), altered weights and histopathology of reproductive organs, and reduced semen quality (Hotchkiss et al. 2008, Christiansen et al. 2009, 2010, Axelstad et al. 2011, Hass et al. 2012, Jacobsen et al. 2012). The environmental agents that cause these effects often have many modes of action, but for simplicity, they are here described as being estrogenic or anti-androgenic. For both classes of compounds, it has also been shown that they can act together to produce effects at doses that individually are not associated with any observable responses (Silva et al. 2002, Hass et al. 2007, 2012, Metzdorff et al. 2007, Howdeshell et al. 2008, Rider et al. 2008, 2010, Christiansen et al. 2009, Jacobsen et al. 2012). A majority of in vivo mixture studies have tested the combinations of anti-androgenic compounds and although the doses applied in these experiments have been in the range of no-observed-adverse-effect levels (NOAELs), they were still quite far from environmental exposures experienced by humans. Furthermore, those studies have primarily been designed to explore the predictability of mixture effects, by using various assessment concepts, rather than to investigate environmentally relevant combinations.
Based on this lack of knowledge about effects caused by environmentally relevant contaminant exposures, we have previously performed an exploratory in vivo study in rats, with a mixture of 13 endocrine-disrupting chemicals, modeled on information about environmental exposures in humans (Christiansen et al. 2012). As described in more detail in Christiansen et al. (2012), the chemicals for the mixture were selected based on information about their endocrine-disrupting effects in vivo and available data about human exposures, to guide the choice of doses to be combined in the mixture. Other chemicals could not be included in the mixture because either their effects or their human exposures were not known, and this has constrained somewhat the selection of chemicals for the mixtures investigated in this study. Of the 13 selected chemicals, eight had predominantly anti-androgenic properties. These included the two phthalates – di-n-butyl phthalate (DBP) and di-(2-ethylhexyl) phthalate (DEHP), the five pesticides – vinclozolin, prochloraz, procymidine, linuron, epoxiconazole, and the DDT metabolite \( p,p'\)-DDE. The mixture also included four predominantly estrogenic substances, the two u.v.-filters octyl methoxy-cinnamate (OMC) and 4-methyl-benzylidene camphor (4-MBC), the phenolic compound bisphenol A (BPA), and the preservative butyl paraben (BP). Furthermore, the mixture included the analgesic drug paracetamol, which has previously been shown to act as an anti-androgen (Kristensen et al. 2011, 2012). Table 1 gives an overview of the uses of these chemicals, their predominant modes of action in causing reproductive tract alterations in experimental animals, some of the relevant effects seen in rodents, together with the NOAELs and lowest-observed-adverse-effect levels (LOAELs) reported in the literature for these effects. More information about each of the chemicals and the rationale for selecting these 13 chemicals for the mixture are presented in detail in Christiansen et al. (2012).

We used information about the potency of the selected chemicals to predict the effects of the mixture by using the point-of-departure index (PODI). This cumulative risk assessment method assumes that the joint action of mixture components can be approximated by dose addition, and that antagonisms or synergisms are not relevant (Christiansen et al. 2012), a conjecture that is supported by empirical evidence (Hass et al. 2007, Howdeshell et al. 2008, Rider et al. 2008, 2010, Christiansen et al. 2009). The method uses NOAELs or benchmark doses of the individual components as input values, together with the dose of each component present in the mixture. Assuming that all mixture components act together according to dose addition, significant combination effects are only expected to occur if the PODI is \( >1 \). The PODI for the combination of the 13 adjusted human high exposure estimates summed up to 0.016 (Table 2). This means that a mixture of dose 1.12 mg/kg per day, equal to the sum of the adjusted high-end human intakes, was not expected to produce any endocrine-disrupting effects in the rat. Even an increase in all individual doses by a factor of 62, which would bring the PODI to 1, would not be expected to produce observable joint effects. In the previous exploratory study, the primary focus was to investigate how developmental exposure to mixtures of all chosen chemicals (at doses equivalent to 150- and 450-fold high-end human exposures) affected early markers of endocrine disruption (Christiansen et al. 2012), and to investigate reproductive effects in adult and senescent offspring (Isling et al. 2013). These doses may appear quite high at first glance, but are indeed highly relevant considering the known differences in toxicokinetics between rat and humans. It is widely accepted that higher doses need to be administered to rats to achieve comparable effects, and this is the basis for using default uncertainty factors of 100 for the extrapolation of effects in rats to humans. The study showed that even the low mixture dose (TotalMix150) caused some signs of anti-androgenic effects, as the numbers of retained nipples in the male offspring was slightly but significantly elevated compared with untreated controls. As anticipated on the basis of the PODI calculations, the male offspring exposed to the high-dose mixture (TotalMix450) showed anti-androgenic effects, including significantly increased NR and reduced weights of the ventral prostate. Exposure only to a mixture of the anti-androgenic components of the mixture (AAMix450) also caused increased NR, whereas no significant effects on reproductive organ weights were seen.

In this study, we expanded our previous investigation on early markers of endocrine disruption, after developmental exposure to a mixture of 13 contaminants (TotalMix), by comparing the effects of the total mixture with the effects of each of its subcomponents, i.e. the anti-androgens (AAMix), the estrogens (EMix), and paracetamol (PM), separately. The statistical power was increased by including larger size groups \( (n=14–20) \) than in the exploratory study, and we placed emphasis on investigating even lower human-relevant doses, and included a dose only 100 times larger than high-end human intakes. Detailed studies on the effects of endocrine-disrupting mixture on sexual maturation, mammary development, sperm count, estrous cyclicity, behavior, serum biomarkers, reproductive organ histology in males and females, and gene expression studies on prostate and mammary gland are ongoing and will be presented in other papers.

**Materials and methods**

**Test compounds**

The test compounds in this study were DBP (purity > 99.0%, Cas no. 84-74-2), DEHP (purity > 99.5%, Cas no. 117-81-7), vinclozolin (purity > 99.5%, Cas no. 50471-44-8), prochloraz (purity > 98.5%, Cas no. 67747-09-5), procymidine...
<table>
<thead>
<tr>
<th>Chemical</th>
<th>Use</th>
<th>Mechanisms of action</th>
<th>Reproductive tract alterations</th>
<th>Effects on AGD and NR</th>
<th>NOAEL (mg/kg per day)</th>
<th>LOAEL (mg/kg per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoxiconazole</td>
<td>Triazole fungicide</td>
<td>The site of action is possible lyase function of CYP17 in steroidogenesis (Taxvig et al. 2007)</td>
<td>No reproductive tract malformations detected, marked fetotoxicity in dams that were unable to deliver (Taxvig et al. 2007)</td>
<td>No effects (Taxvig et al. 2007)</td>
<td>15 (Taxvig et al. 2007)</td>
<td>–</td>
</tr>
<tr>
<td>4-MBC</td>
<td>u.v.-filter</td>
<td>Estrogenic (Schlumpf et al. 2001, Schreurs et al. 2002, Tinwell et al. 2002), possess in vitro AR antagonist potential (Ermler et al. 2010)</td>
<td>Delay of prepubertal separation and decreases in ventral prostate weight (Durrer et al. 2007)</td>
<td>–</td>
<td>0.7 (Durrer et al. 2007)</td>
<td>7 (Durrer et al. 2007)</td>
</tr>
<tr>
<td>OMC</td>
<td>u.v.-filter</td>
<td>Estrogenic (Schlumpf et al. 2001), possess in vitro AR antagonist potential (Ermler et al. 2011)</td>
<td>Decreased testosterone levels and decreased relative weight of testis (g/100 g BW) at PND 16, reduced sperm count at 8 months of age (Axelstad et al. 2011)</td>
<td>–</td>
<td>–</td>
<td>500 (Axelstad et al. 2011)</td>
</tr>
</tbody>
</table>

(continued)
O99.5%, Cas no. 32809-16-8), linuron (purity O99.0%, Cas no. 330-55-2), epoxiconazole (purity O99.0%, Cas no. 106325-08-8), OMC (purity O98.0%, Cas no. 5466-77-3), \( p,p\)-DDE (purity O98.5%, Cas no.72-55-9) were purchased from VWR – Bie and Berntsen (Herlev, Denmark). While 4-MBC (purity O98.0%, Cas no. 36861-47-9), BPA (purity O99.5%, Cas no. 80-05-7), BP (purity O99.0%, Cas no. 94-26-8), and paracetamol (purity O99.0%, Cas no. 103-90-2) were purchased from Sigma–Aldrich, corn oil, which was used both as a control compound and as a vehicle, was purchased from VWR – Bie and Berntsen. Animals and exposure

A total of 156 time-mated nulliparous, young adult Wistar rats (HanTac:WH, SPF, Taconic Europe, Ejby, Denmark) were supplied at gestation day 3 (GD 3) of pregnancy. The study was performed using four blocks of 38–40 dams (separated by 1 week), and all groups were equally represented in the blocks. Animal experiments were carried out at the DTU National Food Institute (Mørkhøj, Denmark) facilities. Ethical approval was obtained from the Danish Animal Experiments Inspectorate. The authorization number is: 2012-15-2934-00089 C4. The experiments were overseen by the National Food Institutes in-house Animal Welfare Committee for animal care and use.

The animals were housed in pairs until GD 17 and alone thereafter under standard conditions in semi-transparent polycarbonate type III cages (1291H Eurostandard Type III, Tecniplast) (15 × 27 × 43 cm) with Aspen wood chip bedding (Tapvei, Gentofte, Denmark), Enviro-Dri nesting material (Brogaarden, Lynge, Denmark), and plastic shelters (Brogaarden). They were housed in an animal room with controlled environmental conditions with a 12 h light:12 h darkness cycle with 500 lux light intensity starting at 2100 h, humidity 55% G 5, temperature at 21 G 1 8 C, and ventilation, changing air ten times per hour. All animals were fed on a standard diet with ALTROMIN 1314 (soy- and alfalfa-free, ALTROMIN GmbH, Lage, Germany). Acidified tap water (to prevent microbial growth) in polycarbonate bottles (Tecniplast) was provided ad libitum.

On the day after arrival (GD 4), the time-mated dams were pseudo-randomly distributed into nine groups with similar body weight (BW) distributions. The dams received vehicle (controls), or one of the eight mixtures presented in Table 2. These included three doses of total mixture (TotalMix100, TotalMix200, TotalMix450), two doses of anti-androgens only (AAMix200, AAMix450), two doses of estrogens only (EMix200, EMix450), and paracetamol (PM). As can be seen in Table 3, 16 and 20 mated dams were used in each dose group, resulting in 14 and 20 viable litters per group. Dams that did not give birth were omitted from the experiment. Mixtures and vehicle were administered by oral gavage with a stainless steel probe 1.2 × 80 mm (Scanbur, Karlslunde, Denmark) from GD 7 to the day before expected birth (GD 21) and again after birth from PND 1 to PND 22 to cover the most sensitive windows of reproductive development in rat offspring. The day the vaginal plug was detected was designated as GD 1 and the expected day of delivery (GD 23) was designated as pup day (PD 1).
Table 2 Dose selection for the experimental studies.

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Adjusted intakes chosen as basis for mixture study (mg/kg per day)</th>
<th>Points of departure POD (AGD, NR) (mg/kg per day)</th>
<th>Ratio of adjusted intakes to POD</th>
<th>Mixture dose (mg/kg per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total-Mix100</td>
</tr>
<tr>
<td>DBP</td>
<td>0.01</td>
<td>50(1)</td>
<td>0.0002</td>
<td>1</td>
</tr>
<tr>
<td>DEHP</td>
<td>0.02</td>
<td>5(1)</td>
<td>0.0067</td>
<td>1</td>
</tr>
<tr>
<td>Vinclozolin</td>
<td>0.003</td>
<td>5(1)</td>
<td>0.0018</td>
<td>0.9</td>
</tr>
<tr>
<td>Prochloraz</td>
<td>0.014</td>
<td>5(1)</td>
<td>0.0028</td>
<td>1.4</td>
</tr>
<tr>
<td>Procydimeone</td>
<td>0.015</td>
<td>10(1)</td>
<td>0.0015</td>
<td>1.5</td>
</tr>
<tr>
<td>Linuron</td>
<td>0.0006</td>
<td>25(1)</td>
<td>0.000024</td>
<td>0.06</td>
</tr>
<tr>
<td>Epoxiconazole</td>
<td>0.01</td>
<td>15(1)</td>
<td>0.0007</td>
<td>1</td>
</tr>
<tr>
<td><em>p,p</em>-DDE</td>
<td>0.001</td>
<td>10(2)</td>
<td>0.0001</td>
<td>0.1</td>
</tr>
<tr>
<td>4-MBC</td>
<td>0.06</td>
<td>5(1)</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>OMC</td>
<td>0.12</td>
<td>30(1)</td>
<td>0</td>
<td>0.15</td>
</tr>
<tr>
<td>Bisphenol A</td>
<td>0.0015</td>
<td>30(1)</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Butyl paraben</td>
<td>0.06</td>
<td>350(2)</td>
<td>0.0023</td>
<td>80</td>
</tr>
<tr>
<td>Sum (mg/kg per day)</td>
<td>1.12</td>
<td></td>
<td>0.016</td>
<td>112</td>
</tr>
</tbody>
</table>

The composition of the tested mixtures and the rationale for the selected doses. Each of the 13 compounds was included in the total mixture in a dose based on the adjusted human intakes (1st column). The points of departure were either NOAELs or LOAELs for effects on anogenital distance (AGD) or nipple retention (NR) in previous studies, and for each compound a ratio of adjusted intakes to the point of departure was calculated by dividing the two values. The eight right columns represent the composition of each of the tested dose groups. See Christiansen et al. (2012) for estimates of high-end human intakes and for the adjusted intakes which were chosen as basis for the mixture study. NOAEL, LOAEL, see Table 1, lack of information about doses affecting AGD or NR, dams dosed with paracetamol alone or in mixture only from GD 13 to GD 19 and after birth from PD 14 to PD 22, in order to avoid problems with parturition.

On PD 16, one male pup and, on PD 17, one female pup per litter were weighed (BW) and decapitated. Malformations of the skin of the offspring were registered. For comparison with the previous study, skin was treated with dilute KOH solution and then viewed through the skin, and then dichotomised in terms of presence or absence of NR, i.e. a yes or no answer for each pup. On PD 16, the skin was treated with dilute KOH solution and then viewed through the skin, and then dichotomised in terms of presence or absence of NR, i.e. a yes or no answer for each pup. The registration criterion used for assessing NR was that the skin was treated with dilute KOH solution and then viewed through the skin, and then dichotomised in terms of presence or absence of NR, i.e. a yes or no answer for each pup. The registration criterion used for assessing NR was that the skin was treated with dilute KOH solution and then viewed through the skin, and then dichotomised in terms of presence or absence of NR, i.e. a yes or no answer for each pup. The registration criterion used for assessing NR was that the skin was treated with dilute KOH solution and then viewed through the skin, and then dichotomised in terms of presence or absence of NR, i.e. a yes or no answer for each pup.
Table 3: Data of pregnancy and litter from gestationally and perinatally exposed rat dams.

<table>
<thead>
<tr>
<th>Mixture dose</th>
<th>No. of dams (litters)</th>
<th>Dam BW-gain, GD 7–GD 21</th>
<th>Dam BW-gain, GD 7–PD 1</th>
<th>Dam BW-gain, PD 1–13</th>
<th>Gestation length</th>
<th>Percentage of post-implantation loss</th>
<th>Percentage of perinatal loss</th>
<th>Litter size</th>
<th>Percentage of males</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>20 (20)</td>
<td>91.83 ± 3.82</td>
<td>21.2 ± 2.40</td>
<td>36.4 ± 3.11</td>
<td>23.1 ± 0.12</td>
<td>5.47 ± 1.99</td>
<td>8.19 ± 2.44</td>
<td>11.05 ± 0.74</td>
<td>46.37 ± 4.99</td>
</tr>
<tr>
<td>Mixture of 13 compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TotalMix100</td>
<td>20 (19)</td>
<td>91.21 ± 3.51</td>
<td>17.9 ± 2.35</td>
<td>32.1 ± 1.99</td>
<td>23.05 ± 0.05</td>
<td>9.30 ± 2.53</td>
<td>10.57 ± 2.76</td>
<td>11.05 ± 0.74</td>
<td>46.38 ± 4.08</td>
</tr>
<tr>
<td>TotalMix200</td>
<td>16 (14)</td>
<td>92.56 ± 3.42</td>
<td>17.4 ± 1.62</td>
<td>33.4 ± 1.33</td>
<td>23.07 ± 0.07</td>
<td>7.56 ± 2.37</td>
<td>10.96 ± 2.53</td>
<td>11.21 ± 0.60</td>
<td>56.62 ± 4.20</td>
</tr>
<tr>
<td>TotalMix450</td>
<td>18 (17)</td>
<td>86.46 ± 5.29</td>
<td>16.2 ± 1.62</td>
<td>30.6 ± 3.30</td>
<td>23.21 ± 0.09</td>
<td>19.15 ± 6.78</td>
<td>23.44 ± 7.28</td>
<td>11.01 ± 1.20</td>
<td>51.75 ± 5.17</td>
</tr>
<tr>
<td>Mixture of eight anti-androgens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AAMix200</td>
<td>16 (15)</td>
<td>89.88 ± 5.10</td>
<td>16.7 ± 2.05</td>
<td>25.8 ± 2.57</td>
<td>23.13 ± 0.08</td>
<td>8.94 ± 3.27</td>
<td>11.27 ± 3.29</td>
<td>10.36 ± 0.93</td>
<td>50.34 ± 3.43</td>
</tr>
<tr>
<td>AAMix450</td>
<td>16 (16)</td>
<td>94.18 ± 3.20</td>
<td>11.0 ± 2.32</td>
<td>33.5 ± 1.36</td>
<td>23.19 ± 0.10</td>
<td>7.50 ± 1.99</td>
<td>9.90 ± 3.18</td>
<td>12.00 ± 0.52</td>
<td>47.51 ± 3.52</td>
</tr>
<tr>
<td>Mixture of four estrogenic compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMix200</td>
<td>16 (16)</td>
<td>96.94 ± 2.59</td>
<td>17.3 ± 1.51</td>
<td>40.4 ± 2.22</td>
<td>23.0 ± 0.00</td>
<td>6.51 ± 1.88</td>
<td>8.78 ± 1.81</td>
<td>12.38 ± 0.54</td>
<td>47.17 ± 3.19</td>
</tr>
<tr>
<td>EMix450</td>
<td>18 (17)</td>
<td>93.24 ± 2.97</td>
<td>15.9 ± 1.81</td>
<td>38.5 ± 1.91</td>
<td>23.12 ± 0.08</td>
<td>6.30 ± 1.53</td>
<td>8.04 ± 1.96</td>
<td>11.16 ± 0.39</td>
<td>45.27 ± 3.22</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>16 (16)</td>
<td>88.55 ± 4.82</td>
<td>16.0 ± 1.85</td>
<td>31.4 ± 2.51</td>
<td>23.09 ± 0.07</td>
<td>16.58 ± 5.42</td>
<td>22.12 ± 5.64</td>
<td>10.31 ± 0.91</td>
<td>47.52 ± 3.10</td>
</tr>
</tbody>
</table>

Body weight (BW) gain during gestation and lactation, in rat dams exposed to mixtures of endocrine-disrupting chemicals from gestation day (GD) 7 to pup day (PD) 22, as well as the postimplantation and perinatal loss of offspring, calculated by comparing number of implantations to number of live pups. Data represent group mean ± S.E.M. *Values are statistically significantly different from controls and are marked in bold (P<0.05).
Table 4 Data of male offspring.

<table>
<thead>
<tr>
<th>Mixture dose</th>
<th>Body weight (g)</th>
<th>AGD index</th>
<th>Body weight (g)</th>
<th>Nipple retentiona (only block 3 and 4)</th>
<th>Offspring</th>
<th>Litters</th>
<th>n</th>
<th>Body weight (g)</th>
<th>Tests (g)</th>
<th>Ventral prostate (g)</th>
<th>Epididymides (g)</th>
<th>Seminal vesicle (g)</th>
<th>LABC (g)</th>
<th>Bulbourethral gland (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>6.31 ± 0.10</td>
<td>11.69</td>
<td>± 0.11</td>
<td>27.86</td>
<td>6% (3/52)</td>
<td>30% (3/10)</td>
<td>18</td>
<td>32.99 ± 1.01</td>
<td>0.1086</td>
<td>0.0120</td>
<td>0.0236</td>
<td>0.0087</td>
<td>0.0293</td>
<td>0.0016 ± 0.0014</td>
</tr>
<tr>
<td>TotalMix100</td>
<td>6.28 ± 0.09</td>
<td>11.53</td>
<td>± 0.13</td>
<td>27.24</td>
<td>16% (7/45)</td>
<td>44% (4/9)</td>
<td>14</td>
<td>31.71 ± 0.89</td>
<td>0.1096</td>
<td>0.0123</td>
<td>0.0220</td>
<td>0.0088</td>
<td>0.0258</td>
<td>0.0018 ± 0.0014</td>
</tr>
<tr>
<td>TotalMix200</td>
<td>6.54 ± 0.14</td>
<td>11.15b</td>
<td>± 0.12</td>
<td>28.22</td>
<td>13% (5/40)</td>
<td>50% (4/8)</td>
<td>12</td>
<td>33.63 ± 0.98</td>
<td>0.1093</td>
<td>0.0108</td>
<td>0.0219</td>
<td>0.0095</td>
<td>0.0254</td>
<td>0.0018 ± 0.0017</td>
</tr>
<tr>
<td>TotalMix450</td>
<td>6.33 ± 0.10</td>
<td>11.14b</td>
<td>± 0.16</td>
<td>27.05</td>
<td>47% (15/32)</td>
<td>86% (6/7)b</td>
<td>15</td>
<td>31.87 ± 0.96</td>
<td>0.1111</td>
<td>0.0092b</td>
<td>0.0225</td>
<td>0.0087</td>
<td>0.0249</td>
<td>0.0015 ± 0.0013</td>
</tr>
<tr>
<td>Mixture of eight anti-androgenic compounds</td>
<td>6.45 ± 0.11</td>
<td>11.32b</td>
<td>± 0.12</td>
<td>27.76</td>
<td>33% (11/33)b</td>
<td>71% (5/7)b</td>
<td>13</td>
<td>33.24 ± 1.13</td>
<td>0.1121</td>
<td>0.0102b</td>
<td>0.0230</td>
<td>0.0086</td>
<td>0.0263</td>
<td>0.0018 ± 0.0012</td>
</tr>
<tr>
<td>AAMix450</td>
<td>6.37 ± 0.09</td>
<td>11.12b</td>
<td>± 0.07</td>
<td>26.39</td>
<td>72% (23/32)b</td>
<td>100% (8/8)</td>
<td>15</td>
<td>31.16 ± 0.82</td>
<td>0.1168c</td>
<td>0.0086c</td>
<td>0.0209</td>
<td>0.0074</td>
<td>0.0223c</td>
<td>0.0013 ± 0.0009</td>
</tr>
<tr>
<td>Mixture of four estrogenic compounds</td>
<td>6.24 ± 0.10</td>
<td>11.63</td>
<td>± 0.13</td>
<td>26.38</td>
<td>17% (5/29)</td>
<td>29% (2/7)</td>
<td>15</td>
<td>32.66 ± 0.94</td>
<td>0.1066</td>
<td>0.0118</td>
<td>0.0245</td>
<td>0.0095</td>
<td>0.0273</td>
<td>0.0019 ± 0.0015</td>
</tr>
<tr>
<td>EMix450</td>
<td>6.26 ± 0.08</td>
<td>11.91</td>
<td>± 0.17</td>
<td>26.91</td>
<td>17% (5/30)</td>
<td>50% (4/8)</td>
<td>14</td>
<td>32.39 ± 0.85</td>
<td>0.1042</td>
<td>0.0111</td>
<td>0.0246</td>
<td>0.0095</td>
<td>0.0289</td>
<td>0.0018 ± 0.0012</td>
</tr>
<tr>
<td>Paracetamol PM</td>
<td>6.38 ± 0.09</td>
<td>11.50</td>
<td>± 0.14</td>
<td>28.57</td>
<td>38% (12/32)b</td>
<td>75% (6/8)</td>
<td>15</td>
<td>34.81 ± 1.32</td>
<td>0.1154</td>
<td>0.0117</td>
<td>0.0236</td>
<td>0.0091</td>
<td>0.0258b</td>
<td>0.0019 ± 0.0012</td>
</tr>
</tbody>
</table>

Body weights, AGD index, nipple retention, body and reproductive organ weights from male offspring exposed perinatally to the tested mixtures of endocrine-disrupting compounds. Data shown are means ± S.E.M. LABC (MIX450): one high outlier (0.0422), testes (MIX200): one low outlier (0.01440). Data are shown as percent offspring (first column) and percent litters (second column) in each dose group where areolas and/or nipples were registered. Values are statistically significantly different from controls and are marked in bold (P < 0.05). Mixture of eight anti-androgenic compounds; values statistically significantly different from the 13-component mixture are underlined (P < 0.05).
see section on supplementary data given at the end of this article) were unaffected when measured at birth and on days 6, 13, and 16/17.

A statistically significant decrease in AGD was seen in males exposed to mixtures containing anti-androgenic compounds, at median and high doses (TotalMix200, TotalMix450, AAMix-200, and AAMix450). This effect was seen both when analyzed as AGD index (AGDI), (Table 4 and Fig. 1) and when the AGDs were analyzed with the birth weight of the pups as a covariate (data not shown). For the groups exposed to the mixture of anti-androgens only, the effects were dose dependent, as the high dose caused a larger reduction than the medium dose, whereas both doses together with the estrogenic compounds reduced male AGDs similarly (TotalMix200, TotalMix450). The estrogen mixture and PM on its own did not significantly affect male AGDs. In female offspring no significant effects on AGD were seen in any dose group (Supplementary Table 1).

The registration of NR from animals in blocks 3 and 4 is shown as percent of affected offspring and percent of affected litters in each dose group (Table 4). Registration of pups with visible areolas from the last two study blocks showed a statistically significant increase in NR in the group exposed to the highest mixture of all 13 compounds (TotalMix450), the low and the high doses of the anti-androgenic mixtures (AAMix200 and 450) and to paracetamol (the PM group). When registered only as nipple buds in males from the whole data set, the number of nipples was significantly increased in the same three mixture groups as described earlier, whereas the effect was not statistically significant in the PM group (data not shown). The number of nipple buds in female offspring was not affected in any dose group (Supplementary Table 1).

In PD 16, ventral prostate weights were significantly reduced in males in the TotalMix450 group and in the AAMix200 and AAMix450 groups (Table 4). The LABC weights were also significantly decreased at PD 16 (Table 4). Although a slight effect was seen in all TotalMix groups, the reduction in LABC weights was only statistically significant in the AAMix450 and the PM groups. No malformations of external male genitalia were noted. No statistically significant difference in thyroid histopathology scores was observed between males from the TotalMix450 group and controls (data not shown).

In female offspring killed at PD 17, no difference was observed for weight the of uterus or thyroid gland. Ovary weights were significantly increased in the TotalMix450 and AAMix450 groups (Supplementary Table 1), but comparison with results from the exploratory study indicated that this might be a chance finding.

Discussio

Significant effects on AGD, NR, and reproductive organ weights were seen in male offspring exposed to mixtures of the tested endocrine-disrupting chemicals. The majority of the 13 chemicals were present at doses below their NOAELs for endpoints relevant to disruption of male sexual differentiation. Our mixture study shows that combination effects can be demonstrated in the rat when endocrine-disrupting compounds are combined at doses 200-fold higher than estimated high-end human exposure levels. As seen in our previous exploratory study (Christiansen et al. 2012), the PODI approach was proved to be a surprisingly useful tool for anticipating the combined effects of environmental contaminants on rat offspring exposed during gestation and lactation.

The AGDs in male offspring exposed to the higher doses of the TotalMix and the AAMix were significantly reduced by 3–5% (4.6, 4.7, 3.2, and 4.9% reduction in TotalMix200, TotalMix450, AAMix200, and AAMix450 respectively). These effect magnitudes were slightly higher than those observed in the previous study, which did not reach statistical significance (AGDI reductions of 1.1, 1.5, and 3.0% at TotalMix150, TotalMix450, and AAMix450 respectively, Christiansen et al. (2012)). These differences between the mean AGDI values in these two studies are within the range of variation normally expected from experiment to experiment (Christiansen et al. 2010). The observed reductions in AGDI seemed to be caused by the anti-androgenic compounds present in TotalMix, as the changes in these groups were similar to the reductions observed in the groups exposed to the anti-androgenic chemicals alone (AAMix). The addition of estrogenic compounds to the mixture did not seem to alter the anti-androgenic response, and exposure to the mixture of estrogens alone did not cause any significant effects on AGDs either. In other cases, estrogenic compounds may affect AGD or contribute additively to adverse effects caused by exposure to anti-androgens.
and some of the estrogenic compounds are known to alter AGD (Boberg et al. 2013, Christiansen et al. 2013). The lack of effect of the estrogens tested in this study could very well be explained by the fact that the doses of these compounds included in the mixture were modeled on human exposure levels, rather than being added to the mixture based on their potency on a given adverse reproductive endpoint.

When the number of nipple buds was used as the endpoint in our data analysis, a significant increase in NR was seen in male offspring exposed to TotalMix450, AAMix200, and AAMix450. When we enhanced the assessment by including areolas as an additional marker for NR, all three groups were confirmed to be significantly affected, despite the fact that the number of animals available for data analysis was reduced by around the half in each treatment group. Moreover, males exposed to paracetamol showed signs of significantly increased NR (Table 4).

In previous studies, we demonstrated that exposure to paracetamol during development can adversely affect male reproductive development in rats, by reducing male AGDs (Kristensen et al. 2011). The selected dose of paracetamol corresponds to a high level of human exposure (i.e. the maximum recommended dose). Such high exposure may seem quite unlikely to occur during the long time span of almost the whole pregnancy and lactation period. On the other hand, it might not have been necessary for paracetamol exposure over such a long time period to experience its adverse reproductive effects. If paracetamol by chance is taken during the most sensitive period of fetal reproductive development, a few days or weeks may be enough to affect the reproductive function of the child later in life. In a recent paper describing endocrine changes in fetal human testis exposed to paracetamol and other painkillers ex vivo, the authors suggested a critical age window for sensitivity to these compounds (Mazaud-Guittot et al. 2013).

In this study, a paracetamol dose of 350 mg/kg per day led to significant increases in NR and reduced the weight of LABC (Table 4), whereas a reduction in AGDI by 1.6% could not be confirmed as statistically significant. This is apparently contradicting our previous study where we observed on average a 4–7% reduced AGDI in fetal rat offspring on GD 21, with the same exposure dose (Kristensen et al. 2011). This disagreement could, however, be explained in terms of a shortened exposure duration of 7 days in this study (GD 13–19), compared with 15 days in the previous one (GD 7–21) and a different age of examination. The anti-androgenic effect of paracetamol in developmentally exposed rats is corroborated by findings of reduced testosterone production in ex vivo fetal rat testes (Kristensen et al. 2011, 2012) and by in vitro findings in adult human testes (Albert et al. 2013). Furthermore, PM exposure during fetal development in humans has also been associated with increased risk of cryptorchidism in several epidemiological studies (Jensen et al. 2010, 2011a, Kristensen et al. 2011, Snijder et al. 2012), indicating that the effects seen in the rats could be indicative of adverse effects in humans. Further examination of endocrine-sensitive endpoints later in life may clarify whether this anti-androgenic effect of paracetamol causes permanent adverse reproductive effects.

The adversity of moderately shortened AGDs or of slightly increased NR in male offspring can be debated. However, as shown in previous toxicity studies, the effects on AGD and NR are highly predictive for increased risk of adverse reproductive toxicity effects later in life, including increased incidence of hypospadias after puberty (McIntyre et al. 2001, Bowman et al. 2003, Welsh et al. 2008, Christiansen et al. 2009). When the alterations in AGD and NR are relatively small, as in this study, we would not expect to see marked effects on genital malformations or reduced phallus length, as seen with more severe reductions in AGD (Welsh et al. 2008, Christiansen et al. 2009). However, even small changes in these endpoints, if significantly different from concurrent controls, should be taken as a sign of disrupted sex hormone action during critical periods of reproductive development.

Furthermore, investigation of AGD has also proven to be a relevant endpoint with regards to disrupted sexual differentiation in humans, as recent epidemiological studies indicate that boys with hypospadias or cryptorchidism have shorter AGDs compared with boys with normal genitalia (Hsieh et al. 2008) and shorter male AGDs have been reported in humans infants prenatally exposed to high levels of phthalates (Swan et al. 2005, Swan 2008).

The observed reductions in ventral prostate weights in 16-day-old males from the TotalMix450, the AAMix200, and the AAMix450 groups indicated that the anti-androgens contributed markedly to the effect of the total mixture, whereas estrogens and paracetamol did not appear to alter ventral prostate weights at this age. This was as expected, as reductions in prepubertal ventral prostate weights have been described after perinatal exposure to anti-androgens (Metzdorff et al. 2007, Christiansen et al. 2009), while the same effect of estrogens has been seen only at high dose levels. The estrogenic u.v.-filter OMC, which is present in the EMix and TotalMix, was found to reduce prepubertal ventral prostate weight only at a dose of 1000 mg/kg BW per day, which is 19 times higher than the dose applied in the highest mixture groups in this study (Axelstad et al. 2011). In adult animals, estrogenic compounds may increase or decrease prostate weights depending on dose level (vom Saal et al. 1997, Putz et al. 2001). Although weights of LABC appeared lower in all TotalMix groups, the LABC weight reduction was only statistically significant in the AAMix450 and the PM groups. LABC weights are known to be sensitive to perinatal anti-androgen exposure (Metzdorff et al. 2007, Christiansen et al. 2009). No significant difference between LABC
weights of the TotalMix450 and the AAMix450 groups was identified, and the presence of the four chosen estrogenic compounds in the TotalMix, did not appear to influence the results at the tested doses.

Interestingly, there were differences between TotalMix450 and AAMix450 groups regarding testis weight, as pups exposed to AAMix450 had larger testes than pups exposed to TotalMix450, although no significant differences were seen in controls. It may be speculated that a slight increasing effect in the anti-androgens on testis weight was counteracted by a slight depressing effect in the estrogenic components of the TotalMix on testis weight. A previous study showed increasing testis weights in 16-day-old male offspring following perinatal exposure to a mixture of anti-androgenic pesticides (Jacobsen et al. 2012), and a study on the estrogenic u.v.-filter OMC showed reduced testis weight in males of the same age, following perinatal exposure (Axelstad et al. 2011).

Increased ovary weights observed in TotalMix-450 and AAMix-450 groups could indicate an influence of anti-androgens on ovarian development. However, comparison of the present results with the results from the exploratory study indicated no exposure-related differences between ovaries from control and exposed animals, which indicates that these results were chance findings.

The results of this study confirm that highly exposed women of reproductive age may not be protected sufficiently against the combined effects of chemicals that affect the hormonal milieu required for proper sexual differentiation. The PODI calculations indicated that doses 62-fold higher than the adjusted high-end human exposure estimates should be tolerated by the rat without signs of disruption of sexual differentiation. In our previous study (Christiansen et al. 2012), adverse effects on NR were demonstrated at 150-fold higher doses, whereas this study showed clear effects on AGD, NR, and prostate weight at 200-fold higher doses.

The concerns about insufficient margins of safety for highly exposed population groups have to be discussed in the context of accessible exposure estimates, and in the light of the limitations of the study and the constraints that we faced when selecting the chemicals for the study. As background exposure to possible environmental contaminants like phthalates, phenols, and parabens does occur, as high individual exposures to one chemical was shown often to be associated with high exposure to the other measured chemicals (Frederiksen et al. 2013a, 2013b). These data indicate that it is conceivable that certain individuals could have higher than average simultaneous exposure to a large part of the chemicals used in this study.

As also discussed in Christiansen et al. (2012), knowledge gaps concerning the in vivo effects of other candidate compounds prevented inclusion of a wider range of chemicals in the mixture. Quantitative Structure–Activity Relationship (QSAR) analyses have predicted that ~10% of the 30 000 chemicals listed in the European Inventory of Existing Commercial Chemical Substances (EINECS) display AR antagonism (Vinggaard et al. 2008, Jensen et al. 2011b). Therefore, the chosen chemicals cannot be regarded as being entirely a representative of the spectrum of combined exposures encountered by human populations. It is likely that the inclusion of a wider range of chemicals would have led to more pronounced disrupting effects and correspondingly lower margins of safety. However, it should be noted that human exposure to many of these agents is intermittent, and not continuous, as in this experiment. The average human exposures may therefore be lower, but as peak exposures during vulnerable periods are critical during fetal reproductive development, then information about average exposures may be of limited value in predicting risks.

The traditional focus of risk assessment on single chemicals is shifting toward considering combination effects (Christiansen et al. 2012). Our work shows that such efforts can be supported by using the PODI method, perhaps even without conducting time-consuming and costly animal experiments. The present data demonstrate that exposure of the developing mammal to a mixture of estrogenic and anti-androgenic chemicals can affect sexual development. As adverse reproductive effects were observed at mixtures reflecting 200 times high-end human exposure, which is relatively close to the safety margin covered by the regulatory uncertainty factor of 100, the results suggest that highly exposed human population groups may not be sufficiently protected against mixtures of endocrine-disrupting chemicals. Further investigation of reproductive effects in adult and
senescent offspring, as well as studies on mammary gland differentiation, gene expression analysis in the developing brain, and effects on neurobehavioral development may clarify if adverse endocrine-disrupting effects can be seen at 100-fold high-end human exposure levels.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/REP-13-0447.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This article is based on work presented at the 7th Copenhagen Workshop on Endocrine Disrupters, which was supported by the Danish Ministry of the Environment – Environmental Protection Agency. Publication of this special issue was supported by the Society for Reproduction and Fertility. The authors, Marta Axelstad, Sofie Christiansen, Julie Boberg, Pernille Rosenskjold Jacobsen, Louise Krag Isling and Ulla Hass have a relationship with the Danish Ministry of the Environment – Environmental Protection Agency as they all give independent scientifically based advice to the Danish EPA. This is financed via an agreement between the Institute and the Danish EPA. Danish EPA is a governmental institution and as such a non-profit organization. The authors’ participation in COW was also financed by this funding from Danish EPA. Dr Andreas Kortenkamp and Martin Scholze have no financial relationship with the Danish EPA. None of the authors have a relationship with the Society for Reproduction and Fertility. This work has been supported by a grant from the European Commission, 7th Framework Programme, CONTAME (Contaminant mixtures and human reproductive health – novel strategies for health impact and risk assessment of endocrine disrupters), grant agreement no.: 212502) and by funding from the Danish Environmental Protection Agency.

Acknowledgements
Dorte Lykkegaard Korsbech, Lillian Sztuk, Heidi Letting, Birgitte Møller Plesning, Ulla El-Baroudy, Vibeke Kjær, Sarah Grundt Simonsen, Eva Ferdinandsen and Elise Navntoft are thanked for their excellent technical assistance.

References
EFSA -European Food Safety Authority 2010 Scientific opinion on bisphenol A: evaluation of a study investigating its neurodevelopmental toxicity, review of recent scientific literature on its toxicity and advice on the Danish risk assessment of bisphenol A. EFSA Journal 8 1829.
Frederiksen H, Akoglaede L, Sorensen K, Nielsen O, Main KM, Skakkebaek NE, Juul A & Andersson AM 2013b Bisphenol A and other


MacIntyre BS, Barlow NJ & Foster PM 2012 Adverse effects on sexual development in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. Reproductive Toxicology 34:261–274. (doi:10.1016/repotox.2012.05.090)


McIntyre BS, Barlow NJ & Foster PM 2002 Male rats exposed to linuron in utero exhibit permanent changes in anogenital distance, nipple retention, and epididymal malformations that result in subsequent testicular atrophy. Toxicological Sciences 65:62–70. (doi:10.1093/toxsci/k65.1.62)


vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Gianjam VK, Parmigiani S & Welshons WV 1997 Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. PNAS 94 2056–2061. (doi:10.1073/pnas.94.5.2056)


Silva E, Rajapakse N & Kortenkamp A 2002 Something from "nothing"—eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environmental Science & Technology 36 1751–1756. (doi:10.1021/es0101227)


Received 13 September 2013
First decision 22 October 2013
Revised manuscript received 22 November 2013
Accepted 2 December 2013